Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen

Publication
Article
OncologyONCOLOGY Vol 23 No 4
Volume 23
Issue 4

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

All patients in the trial will have the option to continue taking sunitinib or be switched from placebo to sunitinib. The full data set from this trial is being analyzed and more details will be presented at an upcoming scientific meeting.

Articles in this issue
Despite Past Disappointments the Future of Melanoma Therapy Appears Bright
Everolimus Approved for Advanced Kidney Cancer
Report Shows Record Number of Cancer Drugs in Development
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
Black Cohosh (Cimicifuga racemosa)
Black Cohosh (Cimicifuga racemosa)
Clinical Trials and Radiation Oncology Technologies
Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done?
Current Status and Future Potential of Advanced Technologies in Radiation OncologyPart 2. State of the Science by Anatomic Site
Health Literacy: Improving Patient Understanding
Health Literacy, Communication, and Treatment Decision-Making in Older Cancer Patients
The Role of Adjuvant Radiation in Endometrial Cancer
The Role of Adjuvant Radiation in Endometrial Cancer
Resolving the Confusion Surrounding Adjuvant Radiation in Endometrial Cancer
Studies of Adjuvant Treatment for Endometrial Cancer
Landmark Study Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer
Maintenance Rituximab Useful in Advanced Indolent Lymphoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
CRC Yields Most Prevalent Data at Recent GI Meeting
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Codon 12 Mutations May Signal Benefit With RMC-6236 in PDAC
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Extended Follow-Up May Elucidate How ctDNA Impacts RMC-6236 PDAC Outcomes
AI and Changing the Future of Pancreatic Cancer Screening
AI and Changing the Future of Pancreatic Cancer Screening
Changing the Pancreatic Cancer Landscape Via Liquid Biopsy
Changing the Pancreatic Cancer Landscape Via Liquid Biopsy
Genetic Testing Identifies and Helps to Prevent Pancreatic Cancer
Genetic Testing Identifies and Helps to Prevent Pancreatic Cancer
Liquid Biopsy May Assist With Early Pancreatic Cancer Detection
Liquid Biopsy May Assist With Early Pancreatic Cancer Detection
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
Outlining Screening Demographics for Pancreatic Cancer
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Moving the Needle With Pan-RAS Inhibitors, Vaccines in Pancreatic Cancer
Related Content
Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Tim Cortese
March 26th 2025
Article

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

ONCOLOGY Staff
March 14th 2025
Article

Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

Tim Cortese
March 12th 2025
Article

The OSE2101 cancer vaccine plus FOLFIRI chemotherapy demonstrated positive survival data with minimal toxicities in the phase 2 TEDOPaM trial.

3 Things You Should Know About Recognizing LEMS in Patients With SCLC

3 Things You Should Know About Recognizing LEMS in Patients With SCLC

ONCOLOGY Staff
March 12th 2025
Article

In patients with small cell lung cancer, Lambert-Eaton myasthenic syndrome leads to muscle weakness and can be discovered with no-cost testing such as anti-VGCC antibody testing.